Search Results for: Waldenström's macroglobulinemia

Imbruvica (Ibrutinib)

Imbruvica (ibrutinib) is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, jointly developed and commercialized by Janssen and Pharmacyclics. It is an oral therapy approved, either alone or in combination ... Read more